The RA-related CVR was represented by longer disease duration; 46% of the patients with CVR had the disease duration >10 years, while the percentage of patients with active disease (DAS28 > 3.2) and the frequency of RA-specific autoantibodies RF and ACPA was similar between the groups with CVR and with no CVR (Table 1). This evidence concerns the gene PRTN3 and rheumatoid arthritis.